Ziopharm Oncology (ZIOP) Misses Q3 EPS by 1c

Ziopharm Oncology (NASDAQ: ZIOP) reported Q3 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09).

“During the third quarter, we again made progress in all three programs and strengthened the Board of Directors, Scientific Advisory Board and Executive Team,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer. “Ziopharm is on track to file an IND for the first TCR-T trial early next year and the NCI is taking steps to begin the phase 2 Sleeping Beauty TCR-T trial under their direction. We are pleased by Eden BioCell’s steps to submit an IND for the RPM CAR-T trial in Taiwan to infuse T cells the day after gene transfer and heartened by the initial reports we are receiving regarding the first patients dosed by Eden BioCell and partners under compassionate use. Later this month, we will share data from our Controlled IL-12 program at the 2020 Society for Neuro-Oncology Annual Meeting.”

For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• First Mid Bancshares, Inc. (FMBH) Tops Q1 EPS by 8c
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance